Related Experiment Video
Updated: May 11, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy.
1Biologics Research, Bayer Healthcare Pharmaceuticals, San Francisco, CA, USA.
Journal of Thrombosis and Haemostasis : JTH
|May 23, 2013
Summary
Glycoengineering enhances factor IX (FIX) for hemophilia B treatment. Novel glycosylation sites improve subcutaneous bioavailability and efficacy, potentially enabling less frequent dosing.
Area of Science:
- Biotechnology
- Protein Engineering
- Pharmacology
Background:
- Hemophilia B treatment requires frequent intravenous factor IX (FIX) infusions due to rapid clearance.
- Subcutaneous administration of FIX is desirable but limited by poor bioavailability.
Purpose of the Study:
- To identify optimal positions for novel glycosylation sites on FIX.
- To enhance FIX pharmacokinetics (PK) and bioavailability for subcutaneous delivery.
- To maintain coagulation activity while improving FIX properties.
Main Methods:
- Screened 251 variants with additional N-linked glycosylation sites in vitro.
- Evaluated PK profiles of selected FIX variants in mice.
- Combined optimal variants and assessed their PK and efficacy in a hemophilia B mouse model.
Main Results:
- Selected FIX variants showed improved PK and maintained activity.
- Combining three novel N-glycan sites with the 338A variant significantly enhanced FIX.
- Optimized FIX exhibited 4.5-fold reduced clearance and 2.4-fold increased subcutaneous bioavailability.
- Efficacy was demonstrated at a fivefold lower dose compared to wild-type FIX.
Conclusions:
- Glycoengineering successfully improved FIX subcutaneous PK and efficacy.
- This approach offers potential advantages for subcutaneous FIX dosing in hemophilia B patients.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.